Mathematician Finds Solution to One of The Oldest Problems in Algebra
Solving one of the oldest algebra problems isn't a bad claim to fame, and it's a claim Norman Wildberger can now make: The mathematician has solved what are known as higher-degree polynomial equations, which have been puzzling experts for nearly 200 years.
Wildberger, from the University of New South Wales (UNSW) in Australia, worked with computer scientist Dean Rubine on a paper that details how these incredibly complex calculations could be worked out.
"This is a dramatic revision of a basic chapter in algebra," says Wildberger. "Our solution reopens a previously closed book in mathematics history."
As you might expect, understanding how this works isn't easy for the non-algebra geniuses amongst us. Essentially, polynomials are equations that include variables raised to non-negative powers (e.g. x3). When those powers are five or above, that's a higher-degree polynomial.
Mathematicians have figured out how to solve lower-degree versions, but it was thought that properly calculating the higher-degree ones was impossible. Before this new research, we've been relying on approximations.
Wildberger and Rubine took a new approach to the problem, which is based on Catalan numbers. These numbers are used in advanced number counting and arrangements, including counting how many ways polygons can be subdivided into triangles.
By extending the idea of Catalan numbers, the researchers were able to demonstrate that they could be used as a basis for solving polynomial equations of any degree. Part of the clever method involved extending polygon counts to other shapes besides triangles.
It's a departure from the traditional method of using radical expressions (like square roots and cube roots) to solve equations like this, instead relying on combinatorics – counting numbers, fundamentally, but in increasingly advanced ways.
"The Catalan numbers are understood to be intimately connected with the quadratic equation," says Wildberger.
"Our innovation lies in the idea that if we want to solve higher equations, we should look for higher analogs of the Catalan numbers."
The researchers put their new algebra up against some well-known polynomial equations of the past, including a famous cubic equation studied by John Wallis. The numbers checked out, validating the new work.
Wildberger and Rubine didn't stop there. They also discovered a new mathematical structure called the Geode, which ties in with Catalan numbers and seems to act as a foundation for them. This Geode could form the basis of many future studies and discoveries, the researchers say.
As the approach taken here is so different to what's gone before, there's the potential to rethink many key ideas that mathematicians have long relied on for computer algorithms, the way data is structured, and game theory. It might even have applications in biology – for counting RNA molecule folding, for example.
"This is a core computation for much of applied mathematics, so this is an opportunity for improving algorithms across a wide range of areas," says Wildberger.
The research has been published in The American Mathematical Monthly.
Scientists Build First-Ever 'Black Hole Bomb' Analog
Gravity May Be a Clue That The Universe Is a Giant Computer
Scientists Just Confirmed a 67-Year-Old Hypothesis About Vitamin B1
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
Engineers unveil radical new freight system that could make diesel trucks obsolete: 'Almost like a mini-airline'
A team of engineers from the University of New South Wales is developing a fleet of drones that can deliver vital supplies to remote areas of Australia. The all-electric fleet would produce zero emissions and be a game-changer for both the population of these remote areas and the environment at large. Countries like Australia have vast swaths of remote land. The population of these remote areas depends on diesel trucks for the delivery of vital materials such as food and medicine. But the emissions from those long deliveries can be detrimental to both the environment and the humans they are serving. Diesel trucks are one of the largest sources of emissions around the globe, contributing to human respiratory illnesses such as asthma and lung disease. They are also detrimental to the environment, as they can degrade crops and soil as well as produce acid rain. To top it all off, they contribute mightily to warming temperatures around the globe. The project is a collaboration between a company called Seaflight Technologies and Macquarie University. Together, they are developing the AURA-E, an electric drone designed for long-range, heavy cargo transport. The ultimate goal of the program is to create a drone that can carry 440-660 pounds over hundreds of kilometers. The leaders of the program believe its benefits will go beyond efficiency and being better for the environment. It should also be a significant source of job growth in the region. This is because the operation of a fleet of drones will require a new generation of aviation professionals and entrepreneurs. With that in mind, the government of Australia awarded the development team half of the program's $3 million budget. This is only the latest use of drone technology to benefit the environment. It has also been used to locate abandoned oil and gas wells. And they are increasingly being deployed to fight deadly and destructive wildfires before they can spread out of control. The heads of the program have big ideas about its potential scope. "If you imagine drones as being almost like a mini-airline, you could have hundreds or even thousands of flights per day," said Graham Doig, the founder of Seaflight Technologies. He was also understandably enthusiastic about the idea of replacing the dirty diesel trucks. "You can start talking about resupplying a community with medical supplies or fresh fruit and vegetables that otherwise would have come from the other side of the country in a diesel-spewing truck. We're taking that off the road, and we're replacing it with near-zero emissions technology that can provide people with goods they need the next day." Which of the following sustainable changes would make you most likely to choose a particular airline? Using cleaner fuel Reducing in-flight waste Making it easy to choose low-emissions itineraries I don't pay attention to sustainability when I fly Click your choice to see results and speak your mind. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Medscape
5 days ago
- Medscape
Sibeprenlimab Halves uPCR in IgA Nephropathy Trial
VIENNA — Sibeprenlimab, a novel selective immune antibody, reduced the urine protein-to-creatinine ratio (uPCR) by more than half in patients with immunoglobulin A (IgA) nephropathy, according to an interim analysis of the VISIONARY trial. Beyond this clinical effect, a notable observation was the lack of safety concerns, especially given that, although sibeprenlimab is a selective agent, there may have been unexpected off-target effects. 'Safety's been a key consideration with these drugs,' study presenter Vlado Perkovic, MD, PhD, provost and scientia professor, University of New South Wales, Sydney, Australia, told Medscape Medical News . Sibeprenlimab represents a new mechanism of action and 'we don't yet fully understand the profile, so we've been looking at that data very carefully,' explained Perkovic. 'In particular, the infection risk has been my biggest concern, given we know that infections are dramatically increased in people with steroid therapy for example, in IgA nephropathy.' The results of the trial — the largest to date in the field — were presented at the 62nd European Renal Association Congress 2025 on June 6 and drew a warm applause from the audience. An Underestimated Condition IgA nephropathy is estimated to affect 2.5 per 100,000 people per year, although 'it's possible that that number is a significant underestimate,' said Perkovic. Diagnosis typically occurs between 20 and 40 years of age. And, despite supportive care, the majority of patients have a high lifetime risk of end-stage kidney disease (ESKD), with up to 50% of patients progressing to ESKD within 20 years of their clinical presentation. 'It's quite likely we've underestimated just how important this condition is,' said Perkovic, but 'we're fortunate that we're in the middle of something of a golden age of developing new treatments.' A number of therapies have been shown to reduce the risks associated with the disease, although they do not necessarily address the immunological basis of the condition. In addition to newer treatments, 'corticosteroids have long been used for people with IgA nephropathy,' Perkovic said, 'but of course, corticosteroids also have a range of different effects across the immune system,' which can lead to adverse outcomes. Sibeprenlimab is a selective IgG2 antibody that binds to and inhibits the biological activity of APRIL (a proliferation-inducing ligand), which is produced by mucosal epithelial and myeloid cells and binds to B cells. APRIL regulates B-cell-mediated immune responses and mediates IgG and IgA class switching in mature B cells. It is these two actions that make APRIL a key factor in the so-called 4-Hit process in the pathogenesis of IgA nephropathy, which results in the deposition of immune complexes in the glomerulus, leading to proteinuria and loss of kidney function. Phase 3 VISIONARY TRIAL Following on from the successful phase 2 ENVISION trial of sibeprenlimab, the researchers undertook the phase 3 VISIONARY trial, an ongoing study involving patients with biopsy-confirmed IgA nephropathy from 240 sites in 31 countries, who were randomized to sibeprenlimab or placebo for 100 weeks and followed up for a further 12 weeks. All patients were required to have a uPCR of ≥ 0.75 g/g or urine protein excretion of ≥ 1.0 g/day, an estimated glomerular filtration rate (eGFR) of ≥ 30 mL/min/1.73 m2, and to have been on a stable dose of either an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, with or without a SGLT2 inhibitor, for ≥ 3 months prior to screening. For the current pre-specified interim analysis, Perkovic reported the efficacy and safety results in the first 320 randomized patients (152 in the sibeprenlimab group and 168 in the placebo group), focusing on the primary endpoint of 24-hour uPCR at 9 months vs baseline, with eGFR and other data expected to be presented in 2026. The median age of the patients was 42-43 years. There were proportionally fewer females in the sibeprenlimab group (34.2%) vs the placebo group (40.5%). The majority of the patients were Asian, at 61.8% and 56.5%, respectively. Compared with a rise in uPCR at the 9-month follow-up in the placebo group, sibeprenlimab was associated with a 50.2% reduction in uPCR, giving a highly significant placebo-adjusted treatment effect of 51.2% ( P < .0001). Importantly, the benefit of sibeprenlimab on uPCR was seen as early as 4 weeks after initiating treatment and continued to accrue throughout follow-up. Ronald T. Gansevoort, MD, PhD, professor of medicine and a nephrologist at the Department of Nephrology, University Medical Center Groningen, Netherlands, who co-chaired the session, told Medscape Medical News that the results look 'very promising.' 'Recently, we have had several agents working in different ways that all show proteinuria lowering,' he continued, but the results from those studies show that the improvements seen in VISIONARY are 'the best proteinuria lowering' seen so far. Gansevoort noted, however, that this remains an interim analysis, and that he is really looking forward to seeing the kidney function results, adding: 'It was a little bit of a pity that they were not allowed to show at least the 9-month interim data on kidney function, which would have been so interesting.' Safety Results In terms of safety, the proportion of patients experiencing a treatment-related treatment-emergent adverse event (TEAE) was marginally lower with sibeprenlimab, at 32.9% vs 31.0% with placebo. The proportion of patients having a TEAE that led to treatment discontinuation was 0.7% vs 2.4%, respectively, and there were fewer severe and serious TEAEs with the experimental drug. 'If we focus on the infection-related adverse events,' Perkovic said, 'we can see that rates were numerically slightly higher in the sibeprenlimab than the placebo group, with a pattern that was broadly consistent, but with perhaps a slight excess of COVID 19.' He noted that this was 'the reverse of the pattern we've seen in the phase 2 trials, suggesting a chance' outcome. 'The data so far look remarkably encouraging,' he added. There's really no suggestion of an increased risk of infection,' with no opportunistic infections identified, 'and certainly no deaths.' More data is required from the ongoing follow-up to support what has been observed so far, but if the final results do bear out both the efficacy and safety outcome, it will show that sibeprenlimab is 'a precision approach to the fundamental abnormality in IgA nephropathy: that's the really exciting part,' said Perkovic. The study was funded by Otsuka Pharmaceutical Development and Commercialization. Perkovic declares relationships with Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Chinook Therapeutics, Eli Lilly & Company, Gilead Sciences, GlaxoSmithKline, Guard Therapeutics, Incyte, Janssen, Merck, Mitsubishi Tanabe Pharma, Mundipharma, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi, Shaanxi Micot Technology, Travere Therapeutics.
Gizmodo
02-06-2025
- Gizmodo
Scientists Taught People to Change Their Own Brainwaves to Feel Less Pain
In an initial trial, patients who suffer from chronic nerve pain got relief from an interactive game that trained them to alter their own brainwaves. The promising results could lead to a new generation of drug-free treatments, according to the study. A research team led by psychologists from the University of New South Wales in Sydney, Australia developed PainWaive—a training system that teaches users to regulate abnormal brain activity that underlies nerve pain—as a potential in-home, non-invasive alternative to opioids. The results, published in The Journal of Pain in April, showed that three out of four participants saw significant reductions in pain five weeks after the last treatment. The PainWaive system consists of an electroencephalogram (EEG) headset that records brain activity paired with an app that instructs patients on how to control their brainwaves through neurofeedback games, according to a UNSW statement. Four participants who suffer from corneal neuropathic pain—a condition that causes painful hypersensitivity of the eyes, face, or head—underwent 20 PainWaive sessions over the course of four weeks. Doctors aren't sure exactly what causes corneal neuropathic pain, and this condition rarely responds to current treatments, according to the researchers. But they hypothesized that altering brainwaves generally associated with nerve pain could provide relief. 'The brainwaves of people with neuropathic pain show a distinct pattern: more slow theta waves, fewer alpha waves, and more fast, high beta waves,' co-lead author Sylvia Gustin, a clinical psychologist and UNSW professor, said in the statement. Her research has investigated changes in the thalamus—a central brain structure that relays sensory and motor signals to the cerebral cortex—associated with nerve pain. 'We believe these changes interfere with how the thalamus talks to other parts of the brain, especially the sensory motor cortex, which registers pain,' she said. 'I wondered, can we develop a treatment that directly targets and normalizes these abnormal waves?' This curiosity ultimately led to the development and first clinical trial of PainWaive. For this study, Gustin and her colleagues provided four participants with kits that included an EEG headset and a tablet pre-loaded with the game app. Participants also received guidance on mental strategies that can help them shift their brainwaves from an abnormal to a normal state, such as relaxation techniques. The researchers assessed the participants' corneal neuropathic pain symptoms immediately after using PainWaive and five weeks post-treatment. During these follow-ups, participants were encouraged to continue using the brainwave-altering strategies they learned through the training. The results suggest that three of the four participants experienced pain relief comparable to or greater than that offered by opioids, according to UNSW. While these early results are promising, further clinical trials will need to confirm the safety and efficacy of PainWaive. 'Restrictions in the study's size, design and duration limit our ability to generalize the findings or rule out placebo effects,' co-lead author Negin Hesam-Shariati, a researcher at UNSW's NeuroRecovery Research Hub, said in the statement. 'But the results we've seen are exciting and give us confidence to move to the next stage and our larger trial.' Now, she and her colleagues are recruiting participants for two upcoming trials that will investigate PainWaive's potential to reduce chronic spinal pain and chronic nerve pain in people with spinal cord injuries. The development of drug-free pain treatments plays a critical role in combatting the opioid crisis. In the U.S., opioid-related deaths have turned a corner in recent years, with provisional data pointing to a 24% decline between 2023 and 2024. But there is still a need for more non-opioid pain management options. Hesam-Shariati, Gustin, and their colleagues hope that as PainWaive progresses through clinical trials, it will tick all of those boxes. 'Owning the technology offers us the potential to one day offer PainWaive as a truly affordable, accessible solution for at-home pain management, especially for those with limited access to traditional treatments,' Gustin said.
